Azitra

Azitra is a clinical-stage biopharmaceutical company based in Branford, Connecticut, that develops precision dermatology therapies using engineered proteins and live biotherapeutic products to treat rare skin diseases. The publicly traded enterprise operates with a team of 13 employees and utilizes a proprietary microbial library containing approximately 1,500 bacterial strains to discover targeted treatments. Prior to raising $7.5 million in its June 2023 initial public offering, the firm secured over $30 million in private venture funding to advance its clinical pipeline. The company maintains strategic partnerships and financial backing from recognizable entities including Bayer, Bios Partners, and Yale University. Its lead candidate, ATR-12, is currently undergoing Phase 1b clinical trials for Netherton syndrome following FDA clearance to address immune-mediated dermatological conditions. Azitra was founded in 2014 by Travis Whitfill, Azita Haigis, and Choukri Ben Mamoun.